31/10/2025
🎀 As Pink October – Breast Cancer Awareness Month comes to a close, Novartis stands united in our commitment to address breast cancer across Latvia, Lithuania, and Estonia. Shared challenges call for shared commitment, and early detection through regular screenings remains key to saving lives.
📊 Globally, 1 in 20 women will be diagnosed with breast cancer in their lifetime, and 1 woman dies every minute from the disease.
📍In the Baltics, breast cancer remains the most common cancer among women. Despite progress in screening, challenges persist:
- Late-stage diagnosis due to low screening uptake and delayed access, especially in rural areas.
- Awareness gaps among older populations and underserved regions.
This October, Novartis proudly supported Patient Advocacy Groups across the Baltics to amplify the message of early detection:
🇱🇹 Spotlighting breast cancer screening with mobile mammography services in underserved regions.
🇱🇻 Encouraging women to symbolically commit to breast health through the Pink Oath campaign.
🇪🇪 Supporting a powerful campaign to raise awareness of metastatic breast cancer through education and visibility.
💬 At Novartis, our colleagues reflect on what this means in practice:
“Innovation brings hope. Awareness drives action. Community gives strength.”
— Keit Ilau, Estonia
“In small towns, screening is still out of reach. Let’s change that.”
— Virginija Josiene, Lithuania
“The Pink Oath means standing for access, empathy, and early detection.”
— Klāvs Freidenfelds, Latvia
🙏We extend our heartfelt thanks to POLA, Pink train foundation/Rozā vilciena labdarības fonds , Eesti Vähiliit - Elujõu Liit for creating and driving such impactful activities!
Together, we turn awareness into action.
FA-11546002 2025/10